Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
In Japan, premixed insulins are commonly used as starter insulin for type 2 diabetes. This subpopulation analysis assessed the efficacy and safety of twice-daily LM25 (25% insulin lispro/75% insulin lispro protamine) and LM50 (50% insulin lispro/50% insulin lispro protamine) as starter insulin in Japanese subjects, and compared these results with the whole-trial populations of East Asian subjects. In this subpopulation analysis of an open-label, phase 4, randomized trial (CLASSIFY), Japanese subjects received LM25 (n = 88) or LM50 (n = 84) twice-daily for 26 weeks. The primary outcome was change from baseline at Week 26 in glycated hemoglobin (HbA1c). Results for Japanese subjects were generally similar to those for the whole-trial population. Similar changes from baseline in HbA1c were observed for LM25 and LM50 groups (least squares [LS] mean difference [95% confidence interval] of LM25 - LM50 = 0.13 [-0.16, 0.41]%, 1.42 [-1.75, 4.48] mmol/mol, p = 0.388). More LM50-treated subjects than LM25-treated subjects achieved HbA1c targets of <7.0% (59.5% versus 43.2%; p = 0.034) or ≤6.5% (45.2% versus 28.4%; p = 0.027). The reduction in postprandial blood glucose concentrations after morning and evening meals was statistically significantly greater for LM50 than for LM25. The incidence of both hypoglycemia and treatment-emergent adverse events were similar between treatment groups. Both LM25 and LM50 twice daily appear to be effective and well tolerated as starter insulin, although LM50 might be more effective for Japanese type 2 diabetes patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Premixed insulins are popular with some persons, but they provide less dosing flexibility and have been associated with a higher frequency of hypoglycemia compared to basal and basal-bolus regimens in many, but not all studies.1075–1079”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1078]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030
Wild, S. H., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2569-a · Cited by 1,477
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Monnier, L., Colette, C., Dunseath, G. J., & Owens, D. R. (2007) · Diabetes Care · doi:10.2337/dc06-1612 · Cited by 490
Ceriello, A., & Colagiuri, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02565.x · Cited by 268
Fukushima, M., Usami, M., Ikeda, M., Nakai, Y., Taniguchi, A., Matsuura, T., Suzuki, H., Kurose, T., Yamada, Y., & Seino, Y. (2004) · Metabolism · doi:10.1016/j.metabol.2004.02.012 · Cited by 222
Diabetes in Japan: a review of disease burden and approaches to treatment
Neville, S. E., Boye, K. S., Montgomery, W. S., Iwamoto, K., Okamura, M., & Hayes, R. P. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1012 · Cited by 150
Oba, K. (2011) · Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics · doi:10.3143/geriatrics.48.640 · Cited by 121
Qayyum, R., Bolen, S., Maruthur, N., Feldman, L., Wilson, L. M., Marinopoulos, S. S., Ranasinghe, P., Amer, M., & Bass, E. B. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-8-200810210-00242 · Cited by 107
Ilag, L. L., Kerr, L., Malone, J. K., & Tan, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.003 · Cited by 88
Yoshinaga, H., & Kosáka, K. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00019-4 · Cited by 65
The Architecture of Risk for Type 2 Diabetes: Understanding Asia in the Context of Global Findings
Abdullah, N., Attia, J. R., Oldmeadow, C. J., Scott, R. J., & Holliday, E. G. (2014) · International Journal of Endocrinology · doi:10.1155/2014/593982 · Cited by 53
Mukai, N., Doi, Y., Ninomiya, T., Hirakawa, Y., Nagata, M., Yoshida, D., Hata, J., Fukuhara, M., Nakamura, U., Kitazono, T., et al. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12136 · Cited by 53
Mosenzon, O., & Raz, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2007 · Cited by 53
Wu, T., Betty, B., Downie, M. R., Khanolkar, M., Kilov, G., Orr‐Walker, B., Senator, G. B., & Fulcher, G. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0116-0 · Cited by 34
Freemantle, N., Balkau, B., Danchin, N., Wang, E. M., Marre, M., Vespasiani, G., Kawamori, R., & Home, P. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01613.x · Cited by 34
Inzucchi, S. E., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc15-0812 · Cited by 32
Cucinotta, D., Smirnova, O. M., Christiansen, J. S., Kanc, K., Devehat, C. L., Wojciechowska, M., de la Torre, M. L., & Liebl, A. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01035.x · Cited by 26
Giugliano, D., Tracz, M., Shah, S., Calle‐Pascual, A. L., Mistodie, C. V., Duarte, R., Sarı, R., Woo, V. C., Jiletcovici, A., Deinhard, J., et al. (2013) · Diabetes Care · doi:10.2337/dc12-2704 · Cited by 20
Farcaşiu, E., Iványi, T., Możejko-Pastewka, B., Birkus, Z., Csog, J., Kowalska, I., Coetzer, T. F., Bulgurlu, S. S., Schinzel, B., & Kiljanski, J. I. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.10.001 · Cited by 19
Tanaka, M., & Ishii, H. (2010) · Journal of International Medical Research · doi:10.1177/147323001003800231 · Cited by 15
Su, Q., Liu, C., Zheng, H., Zhu, J., Li, P. F., Qian, L., & Yang, W. Y. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12442 · Cited by 14
Self-citationShimizu, H., Monden, T., Matsumura, M., Domeki, N., & Kasai, K. (2010) · Yonsei Medical Journal · doi:10.3349/ymj.2010.51.6.845 · Cited by 13
Watada, H., Su, Q., Li, P. F., Iwamoto, N., Qian, L., & Yang, W. Y. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2816 · Cited by 12
Self-citationGao, F., Zafar, M. I., Ai, X., & Shafqat, R. A. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s75602 · Cited by 8
Qu, Y., Liu, R., Dmitrienko, A. A., & Offen, W. (2011) · Statistics in Medicine · doi:10.1002/sim.4402 · Cited by 8
Wu, T., Betty, B., Downie, M. R., Khanolkar, M., Kilov, G., Orr‐Walker, B., Philips, A., Senator, G. B., & Fulcher, G. R. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(14)70378-x
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Publications from Juntendo University Graduate School of Medicine, 2017 [2/6]
(2019) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.2019.65.4-pl
Metadata
- Authors
- Watada, H., Imori, M., Li, P., & Iwamoto, N.
- Affiliations
- Juntendo University (JP)
- Eli Lilly (Japan) (JP)
- Lilly (China) (CN)
- Venue
- Endocrine Journal
- Publisher
- Japan Endocrine Society
- Published
- 2017
- Volume
- 64
- Issue
- 7
- Pages
- 705-717
- ISSN
- 0918-8959 (ISSN-L)
- 1348-4540
- OpenAlex
- W2617606070
- Cited by
- 2
- References
- 25
- Citations by year
- 2022: 1 · 2019: 1
- FWCI
- 0.22
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Endocrine Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Cell Science Research Foundation
- Abbott Japan
- Kowa Company
- Kissei
- Dainippon Sumitomo Pharma
- Novo Nordisk
- Astellas Pharma
- Shionogi
- Astellas Foundation for Research on Metabolic Disorders
- Ono Pharmaceutical
- Merck Sharp and Dohme
- Eli Lilly Japan
- Novo Nordisk Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin lispro, premixed insulin, type 2 diabetes, Japanese patients, HbA1c, postprandial blood glucose, hypoglycemia, East Asian patients
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Administration Schedule, Asia, Eastern, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Insulin Resistance, Insulin, Isophane, Japan, Male, Middle Aged, Incidence, Postprandial Period, Asian People, Biphasic Insulins, Insulin Lispro
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.